InvestorsHub Logo
Followers 5
Posts 880
Boards Moderated 0
Alias Born 03/04/2024

Re: ATLnsider post# 692155

Thursday, 05/16/2024 7:00:17 PM

Thursday, May 16, 2024 7:00:17 PM

Post# of 701775
Why would Prof Ashkan immediately, upon the close of the DCVAX-L Clinical Trial Patient recruitment in November 2015, recruit more patients for a combi version of the same base treatment for UCLA ?

Was it a UK registered & approved separated clinical trial?
I certainly can’t see that it was contained within the existing MAA filing.

If all true, it doesn’t exactly bode well for the efficacy of DCVAX-L when the lead Investigator was immediately trialling better improved variants upon trial close of the previous less effective version!.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News